Pacira seeks to expand Exparel use in US

Shares of Pacira Pharmaceuticals got a 2.8% boost on 7 May after the company said it was seeking expanded use in the US of its long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) to block nerve pain.

Shares of Pacira Pharmaceuticals got a 2.8% boost on 7 May after the company said it was seeking expanded use in the US of its long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) to block nerve pain.

The Parsippany, New Jersey-based company's stock closed at $74.65, up 78 cents, or 1.06%.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category